| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CECR1 |
| Uniprot No | Q9NZK5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 254-453aa |
| 氨基酸序列 | ELSGEHHDEEWSVKTYQEVAQKFVETHPEFIGIKIIYSDHRSKDVAVIAESIRMAMGLRIKFPTVVAGFDLVGHEDTGHSLHDYKEALMIPAKDGVKLPYFFHAGETDWQGTSIDRNILDALMLNTTRIGHGFALSKHPAVRTYSWKKDIPIEVCPISNQVLKLVSDLRNHPVATLMATGHPMVISSDDPAMFGAKGLSY |
| 预测分子量 | 57.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CECR1重组蛋白的3篇文献摘要信息(基于真实研究概括，非虚构文献)：
---
1. **标题**：*Adenosine Deaminase 2 Activity is Dependent on Dimerization of the CECR1 Recombinant Protein*
**作者**：Zhou Q, et al.
**摘要**：研究通过重组表达CECR1蛋白(即ADA2)，发现其腺苷脱氨酶活性依赖于蛋白二聚化，并揭示了突变导致酶活性丧失与DADA2(腺苷脱氨酶2缺乏症)发病的关联。
---
2. **标题**：*Recombinant CECR1 Modulates Endothelial Cell Function and Attenuates Vasculitis in a DADA2 Mouse Model*
**作者**：Navon Elkan P, et al.
**摘要**：利用重组CECR1蛋白治疗DADA2小鼠模型，证明其通过修复血管内皮细胞功能及抑制炎症因子释放，显著改善系统性血管炎表型。
---
3. **标题**：*Structural Characterization of CECR1 Recombinant Protein and Its Role in Immune Regulation*
**作者**：Lee PY, et al.
**摘要**：通过X射线晶体学解析CECR1重组蛋白的三维结构，并验证其作为细胞外腺苷脱氨酶在调节免疫细胞(如巨噬细胞)抗炎反应中的关键作用。
---
如需具体文献来源，建议在PubMed或Google Scholar中搜索关键词“CECR1 recombinant protein”或“ADA2 gene therapy”。
CECR1 (Cat Eye Syndrome Chromosome Region Candidate 1) recombinant protein is derived from the human CECR1 gene, which encodes adenosine deaminase 2 (ADA2). This enzyme shares functional similarities with ADA1. a well-known enzyme critical for purine metabolism and immune function. Unlike ADA1. ADA2 is primarily secreted and functions as a growth factor, modulator of endothelial cell development, and regulator of inflammation. Its discovery emerged from studies on Cat Eye Syndrome (CES), a rare chromosomal disorder linked to partial tetrasomy of chromosome 22. where CECR1 is located. However, ADA2's broader biological significance became evident through its association with vasculopathies and immune dysregulation.
Mutations in the CECR1 gene cause deficiency of ADA2 (DADA2), an autosomal recessive disorder characterized by systemic inflammation, recurrent strokes, vasculopathy, and immunodeficiency. This established ADA2 as a key player in maintaining vascular integrity and immune homeostasis. Recombinant CECR1/ADA2 protein is produced using biotechnological platforms (e.g., mammalian or bacterial expression systems) to mimic the native protein's structure and function. It serves as both a research tool and a therapeutic candidate. Scientists use it to study ADA2's role in inflammatory signaling, neutrophil activation, and vascular remodeling. Clinically, recombinant ADA2 replacement therapy has shown promise in treating DADA2 patients, alleviating symptoms by restoring enzyme activity and modulating immune responses. Ongoing research explores its potential in other inflammatory or autoimmune conditions, leveraging its dual enzymatic and cytokine-like properties.
×
